Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

ConferenceHBS-301Neutral

AI Analysis

Summary

Harmony Biosciences announced a poster presentation of Phase 3 trial data for HBS-301 (ONSTRIDE-1 and ONSTRIDE-2) at the 17th European Narcolepsy Days conference in Bern, Switzerland on October 2-3, 2026.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Poster presentation of Phase 3 trial data at 17th European Narcolepsy Days

Importance:5/10

Sentiment:

0.00

Phase 3narcolepsyidiopathic hypersomniaconference presentationHBS-301ONSTRIDE-1ONSTRIDE-2

Related Companies

$HRMY

Read the original article

Published by GlobeNewswire Clinical Studies on October 1, 2026 12:05 PM

Read Original